160 related articles for article (PubMed ID: 30325576)
1. Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan.
Ikeda Y; Kubo T; Oda E; Abe M; Tokita S
J Diabetes Investig; 2019 May; 10(3):857-865. PubMed ID: 30325576
[TBL] [Abstract][Full Text] [Related]
2. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
[TBL] [Abstract][Full Text] [Related]
4. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
Levin PA; Zhou S; Gill J; Wei W
J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
[TBL] [Abstract][Full Text] [Related]
5. The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients.
Laires PA; Conceição J; Araújo F; Dores J; Silva C; Radican L; Nogueira A
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):315-25. PubMed ID: 26844705
[TBL] [Abstract][Full Text] [Related]
6. Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study.
Holbrook T; Tang Y; Das R; Shankar RR; Tunceli K; Williams J; Radican L; Holden SE; Morgan CL; Piercy J; Currie CJ
Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28544081
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
8. Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.
Meneghini LF; Lee LK; Gupta S; Preblick R
Diabetes Obes Metab; 2018 May; 20(5):1156-1165. PubMed ID: 29316141
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
Dalal MR; Kazemi M; Ye F; Xie L
Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
[TBL] [Abstract][Full Text] [Related]
10. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.
Giménez M; Elías I; Álvarez M; Quirós C; Conget I
Endocrinol Diabetes Nutr; 2017; 64(7):377-383. PubMed ID: 28745609
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
13. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
[No Abstract] [Full Text] [Related]
14. Approach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool.
Parekh WA; Ashley D; Chubb B; Gillies H; Evans M
Diabet Med; 2015 Sep; 32(9):1156-66. PubMed ID: 25816891
[TBL] [Abstract][Full Text] [Related]
15. The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals.
Yue X; Wu J; Ruan Z; Wolden ML; Li L; Lin Y
Value Health Reg Issues; 2020 May; 21():17-21. PubMed ID: 31634792
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of hypoglycemia among insulin-treated patients with diabetes.
Sussman M; Sierra JA; Garg S; Bode B; Friedman M; Gill M; Kaufman F; Vigersky R; Menzin J
J Med Econ; 2016 Nov; 19(11):1099-1106. PubMed ID: 27292016
[TBL] [Abstract][Full Text] [Related]
17. Is hypoglycemia expensive in China?
Lan K; Wang J; Nicholas S; Tang Q; Chang A; Xu J
Medicine (Baltimore); 2021 Feb; 100(5):e24067. PubMed ID: 33592860
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
[TBL] [Abstract][Full Text] [Related]
19. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
20. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
